Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Morgan Stanley Calls Moderna (MRNA) a Catalyst Driven Idea
January 5, 2023 4:09 PM ESTMorgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $209.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "We expect the first interim analysis from Moderna's Ph3 RSV vaccine study in the near-term. We believe efficacy and safety in-between... More
